Allocation of Listing-Related Proceeds to R&D, Human Resources, and Office Expansion
First written in FY2022-Q2. 2 of 5 entries say "Advanced", first in FY2022. Latest entry: 2026-09-17.
The whole theme swung hardest in 2023: 1 of 7 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- FY2022AdvancedAnnual report
「The funds raised through the public offering at the time of listing and other transactions are being allocated to business expenses, primarily for research and development of therapeutic apps.」
The allocation of the funds raised to business expenses, primarily for research and development, was described as an actual use rather than a planned use. - FY2022-Q3SoftenedAnnual report
「① Research and development funds: ¥1.852 billion is scheduled to be allocated to research and development funds, primarily for the development of therapeutic apps in the DTx product business and clinical trials for various development pipelines (¥248 million for the fiscal year ended June 2022, ¥657 million for the fiscal year ended June 2023 and ¥947 million from the fiscal year ending June 2024 onward). ② Investment in personnel: ¥749 million is scheduled to be allocated to recruitment expenses, including fees paid to recruitment agencies, and personnel expenses to strengthen the systems development, clinical development, business development and administrative functions (¥122 million for the fiscal year ended June 2022, ¥270 million for the fiscal year ended June 2023 and ¥357 million from the fiscal year ending June 2024 onward).」
The framework for using the funds raised remained focused on research and development, investment in personnel and office expansion, while the allocation for research and development was changed from ¥2.061 billion to ¥1.852 billion and the allocation for investment in personnel from ¥779 million to ¥749 million. The stated reasons for the changes were the clarification of the breast cancer app's trial schedule, lower trial costs for the kidney rehabilitation app and delays in the personnel recruitment plan. - FY2022-Q2First statedAnnual report
「Use of funds: funds are scheduled to be allocated to research and development, investment in personnel and expansion of office space」
The funds raised through the third-party allotment are scheduled to be used for research and development, investment in personnel and expansion of office space.